{
    "clinical_study": {
        "@rank": "28224", 
        "arm_group": {
            "arm_group_label": "Verapamil", 
            "arm_group_type": "Experimental", 
            "description": "40 mg Verapamil Per Oral"
        }, 
        "brief_summary": {
            "textblock": "PSVT is a common rhythm disorder in emergency department which can be recurrent in some\n      cases.\n\n      Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very\n      short acting agent.\n\n      Providing a complementary medication to decrease the rate of recurrence of PSVT after its\n      initial control will be promising.\n\n      This study evaluates the role of the oral Verapamil in recurrence control of PSVT in\n      emergency situations."
        }, 
        "brief_title": "Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control", 
        "completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "condition": "Paroxysmal Supraventricular Tachycardia", 
        "condition_browse": {
            "mesh_term": [
                "Tachycardia, Supraventricular", 
                "Tachycardia", 
                "Tachycardia, Ventricular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age>18 years old\n\n          -  PSVT on emergency department presentation\n\n        Exclusion Criteria:\n\n          -  Instability in hemodynamic status\n\n          -  Allergy to Verapamil"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655316", 
            "org_study_id": "16062"
        }, 
        "intervention": {
            "arm_group_label": "Verapamil", 
            "intervention_name": "Verapamil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Verapamil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 12, 2012", 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Recurrence Control", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655316"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Tehran University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tehran University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}